CA2337179A1 - Therapeutic composition based on flavonoids, intended to be used in the treatment of tomours by cytotoxic - Google Patents

Therapeutic composition based on flavonoids, intended to be used in the treatment of tomours by cytotoxic Download PDF

Info

Publication number
CA2337179A1
CA2337179A1 CA002337179A CA2337179A CA2337179A1 CA 2337179 A1 CA2337179 A1 CA 2337179A1 CA 002337179 A CA002337179 A CA 002337179A CA 2337179 A CA2337179 A CA 2337179A CA 2337179 A1 CA2337179 A1 CA 2337179A1
Authority
CA
Canada
Prior art keywords
day
infusion
flavonoid
days
bolus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002337179A
Other languages
English (en)
French (fr)
Inventor
Francis Darro
Robert Kiss
Armand Frydman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon France SAS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2337179A1 publication Critical patent/CA2337179A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
CA002337179A 1998-07-15 1999-07-13 Therapeutic composition based on flavonoids, intended to be used in the treatment of tomours by cytotoxic Abandoned CA2337179A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9809058A FR2781153B1 (fr) 1998-07-15 1998-07-15 Composition therapeutique a base de flavonoides destinee a etre utilisee dans le traitement des tumeurs par des agents cytotoxiques
FR98/09058 1998-07-15
PCT/FR1999/001714 WO2000003706A1 (fr) 1998-07-15 1999-07-13 Composition therapeutique a base de flavonoïdes destinee a etre utilisee dans le traitement des tumeurs par des agents cytotoxiques

Publications (1)

Publication Number Publication Date
CA2337179A1 true CA2337179A1 (en) 2000-01-27

Family

ID=9528648

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002337179A Abandoned CA2337179A1 (en) 1998-07-15 1999-07-13 Therapeutic composition based on flavonoids, intended to be used in the treatment of tomours by cytotoxic

Country Status (12)

Country Link
EP (1) EP1096930A1 (zh)
JP (1) JP2002520356A (zh)
KR (1) KR20020003349A (zh)
CN (1) CN1139384C (zh)
AU (1) AU4789099A (zh)
BR (1) BR9912816A (zh)
CA (1) CA2337179A1 (zh)
EA (1) EA200100140A1 (zh)
FR (1) FR2781153B1 (zh)
IL (1) IL140588A0 (zh)
WO (1) WO2000003706A1 (zh)
ZA (1) ZA200100239B (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170027901A1 (en) * 2015-07-29 2017-02-02 Macau University Of Science And Technology Use of nobiletin in cancer treatment
US20170027900A1 (en) * 2015-07-29 2017-02-02 Macau University Of Science And Technology Use of tangeretin in cancer treatment

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002069949A2 (en) * 2001-03-06 2002-09-12 Prendergast Patrick T Combination therapy for reduction of toxycity of chemotherapeutic agents
EP1808172A3 (en) * 2002-03-06 2010-05-26 Activephyto Technologies Limited Botanical extract compositions and methods of use
DE60313754T2 (de) * 2002-03-06 2008-01-24 The Medical Research and Education Trust, San Diego Botanischer extrakt mit antikrebs-aktivität enthaltend isoliquiritigenin
US20030229136A1 (en) * 2002-04-18 2003-12-11 Nurulain Zaveri Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents
CN1679539A (zh) * 2005-01-20 2005-10-12 吴一心 抗肿瘤的协同药物组合物
WO2006099193A2 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Michigan Chromen-4-one inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
GB0808974D0 (en) * 2008-05-16 2008-06-25 Veritron Ltd Plant extract and its therapeutic use
JP6775226B2 (ja) * 2016-06-30 2020-10-28 国立大学法人広島大学 抗癌剤作用増強物質およびそれを備えた抗癌剤キット
CN106562954A (zh) * 2016-11-11 2017-04-19 黄冈师范学院 (去甲基)多甲氧基黄酮联合紫杉醇类药物在制备治疗非小细胞肺癌的药物上的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0617304B2 (ja) * 1982-09-09 1994-03-09 理化学研究所 制癌剤
JPS5959627A (ja) * 1982-09-27 1984-04-05 Tatsuo Miyoshi 制癌剤
JPS60199817A (ja) * 1984-03-23 1985-10-09 Rikagaku Kenkyusho 制癌剤
JPS632925A (ja) * 1986-06-23 1988-01-07 Nippon Kayaku Co Ltd Ｃキナ−ゼ阻害剤および抗腫瘍剤
FR2633182B1 (fr) * 1988-06-23 1993-07-23 Beljanski Mirko Composition pharmaceutique anticancereuse et methode d'utilisation de l'invention
JPH04103529A (ja) * 1990-08-24 1992-04-06 Tatsuo Miyoshi 制癌剤
JPH04103532A (ja) * 1990-08-24 1992-04-06 Tatsuo Miyoshi 制癌剤
JP2514500B2 (ja) * 1991-09-14 1996-07-10 呉羽化学工業株式会社 多剤耐性抑制剤及び発現阻害剤
EP0642793A4 (en) * 1992-05-11 1995-03-29 Tsumura & Co. Apoptosis inducer.
WO1996031206A2 (en) * 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
DE29719198U1 (de) * 1997-10-29 1998-04-23 Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke, 14558 Bergholz-Rehbrücke Flavono/Flavonoid-Zubereitung

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170027901A1 (en) * 2015-07-29 2017-02-02 Macau University Of Science And Technology Use of nobiletin in cancer treatment
US20170027900A1 (en) * 2015-07-29 2017-02-02 Macau University Of Science And Technology Use of tangeretin in cancer treatment
US9808439B2 (en) * 2015-07-29 2017-11-07 Macau University Of Science And Technology Use of tangeretin in cancer treatment
US9808477B2 (en) * 2015-07-29 2017-11-07 Macau University Of Science And Technology Use of nobiletin in cancer treatment

Also Published As

Publication number Publication date
EA200100140A1 (ru) 2001-06-25
CN1139384C (zh) 2004-02-25
JP2002520356A (ja) 2002-07-09
FR2781153A1 (fr) 2000-01-21
KR20020003349A (ko) 2002-01-12
FR2781153B1 (fr) 2001-08-03
EP1096930A1 (fr) 2001-05-09
ZA200100239B (en) 2002-01-09
CN1313765A (zh) 2001-09-19
WO2000003706A1 (fr) 2000-01-27
IL140588A0 (en) 2002-02-10
BR9912816A (pt) 2001-05-08
AU4789099A (en) 2000-02-07

Similar Documents

Publication Publication Date Title
Liu et al. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes
EP1478355B1 (en) Antitumor compositions containing taxane derivatives
CA2337179A1 (en) Therapeutic composition based on flavonoids, intended to be used in the treatment of tomours by cytotoxic
US20040152643A1 (en) Antitumour combinations containing taxane derivatives and antimetabolites
JPH0349893B2 (zh)
CA2557075A1 (en) Methylation inhibitor compounds
CZ20023228A3 (cs) Farmaceutické prostředky k vyvolání účinku poąkozujícího cévy
Bharti et al. Pathways linked to cancer chemoresistance and their targeting by nutraceuticals
AU761417B2 (en) Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents
WO2011128115A1 (en) Analogues of etoposide for the treatment of tumours
CN101355969A (zh) 包含cyc-682和细胞毒性药物的抗增殖性组合
US20140275214A1 (en) Custirsen treatment with reduced toxicity
EP2107906A2 (fr) Nouvelle utilisation therapeutique pour le traitement des leucemies
CN111494385B (zh) 一种治疗卵巢癌的药物及其制备方法和用途
MXPA01000387A (en) Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents
MXPA01000389A (en) Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents
CN111773388A (zh) A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
JP2016530326A (ja) ロクベンシモツケソウ抽出物及びその用途
EP2558477B1 (en) Analogues of etoposide for the treatment of metastatic tumours
CN113164503B (zh) 3β-O-Glc-DM和20S-O-Glc-DM治疗肺癌或结直肠癌的用途
EP2404608B1 (en) Cholestanol derivative for combined use
WO2005099736A1 (ja) 抗腫瘍治療薬
TR2022021488A2 (tr) Mi̇dekanseri̇ kemoterapi̇ tedavi̇si̇nde kullanilmak üzere geli̇şti̇ri̇len kompozi̇syon
KR20240040601A (ko) 락토바실러스 플란타룸 균주를 포함하는 장내 대사산물 조성의 개선을 위한 조성물
Scarpellini et al. Etoposide, doxorubicin and cisplatin (EAP regimen) in advanced gastric cancer

Legal Events

Date Code Title Description
FZDE Discontinued